GlassScriptPhysician profile
Robin Yc Chan
NPI 1558313932
$15,576.06
in general payments reported to CMS, 2019-2025
45 companies · $2,596 in 2025
The $2,596 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,240 · 2020: $1,711 · 2021: $3,761 · 2022: $2,052 · 2023: $1,012 · 2024: $2,205 · 2025: $2,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,812.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,972.32 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,460.79 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $1,361.10 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,315.97 | 2019-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $1,236.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $1,077.68 | 2021-2025 | |
| Amarin Pharma, INC. | $927.09 | 2019-2023 | |
| Novo Nordisk INC | $757.85 | 2020-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $491.37 | 2019-2025 | Jardiance |
| Ibsa Pharma INC. | $466.14 | 2021-2024 | Licart, Tirosint, Tirosint |
| Pfizer INC. | $335.08 | 2019-2025 | |
| Abbvie INC. | $314.45 | 2020-2025 | |
| Esperion Therapeutics, INC. | $307.58 | 2020-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $299.64 | 2019-2024 | Trulance |
| Merck Sharp & Dohme LLC | $243.22 | 2019-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.